Work

A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.tps663

Authors: Pamela N. Munster, Kathy Miller, Ian E. Krop, Navreet Dhindsa, Joe Reynolds, Elena Geretti, Clet Niyikiza, Ulrik Nielsen, Bart Hendriks, Thomas J. Wickham, Victor M. Moyo, Patricia LoRusso

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Dana-Farber Cancer Institute, Merrimack Pharmaceuticals (United States), The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599045336

Cites:

Cited by: 23

Related to: 10